US2020261601A1PendingUtilityA1
Methods for increasing platelet count by inhibiting biliverdin ixbeta reductase
Assignee: UNIV NEW YORK STATE RES FOUNDPriority: Oct 7, 2015Filed: Dec 11, 2019Published: Aug 20, 2020
Est. expiryOct 7, 2035(~9.2 yrs left)· nominal 20-yr term from priority
A61K 31/713G01N 33/48A61K 48/0066A61P 7/02A61K 48/0083A61K 48/0016C12Y 103/01024A61K 35/19
74
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IXβ reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.
Claims
exact text as granted — not AI-modified1 .- 6 . (canceled)
7 . A pharmaceutical composition comprising a chemical compound that inhibits the enzymatic activity of BLVRB.
8 . The pharmaceutical composition of claim 7 , wherein the BLVRB enzymatic activity is inhibited by at least about 30% to about 100%.
9 . A pharmaceutical composition that inhibits the expression of BLVRB gene, the composition comprising a small interfering RNA (siRNA) molecule or an antisense oligonucleotide specific to a region in the mRNA of the BLVRB gene.
10 . The pharmaceutical composition of claim 9 , wherein the BLVRB gene expression is inhibited by at least about 30% to about 100%.
11 .- 20 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.